Uritone

Quick links to important sections

Uritone

Method of action: Diuretic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uritone

Property Description
Active ingredient Furosemide and Spironolactone
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological class Diuretic and Anti-hypertensive Agent
General purpose Management of excess fluid volume
Origin Synthetic

What Type of Medicine is Uritone?

Uritone is a prescription-only medication defined as a fixed-dose combination product that falls under the high-level therapeutic class of a diuretic and an anti-hypertensive agent. Its components are entirely synthetic in origin, typically manufactured as an oral tablet or a solid preparation intended for ingestion via the oral route. The fundamental classification of diuretics is often recognized as a key method in managing conditions related to fluid retention and hypertension. The specific combination of Furosemide and Spironolactone is a clinically recognized formulation, often seen in similar combined products such as Spiromide or Lasilactone.

The Dual Composition: Furosemide and Spironolactone

The formulation's efficacy is based on the inclusion of two primary active pharmaceutical ingredients: Furosemide and Spironolactone. Furosemide is fundamentally a potent Loop diuretic, a class of medicine known for its rapid ability to increase fluid excretion. Conversely, Spironolactone serves as a Potassium-sparing diuretic and, more specifically, an Aldosterone receptor antagonist. The deliberate combination of a high-ceiling diuretic and a potassium-sparing agent is clinically recognized for achieving robust fluid reduction while stabilizing key electrolyte imbalances.

What is the General Purpose of This Combination Diuretic?

The general purpose of Uritone is to achieve effective volume reduction while providing necessary electrolyte regulation. This is achieved through a combined action that maximizes the urinary excretion of water and sodium using Furosemide, while Spironolactone simultaneously works to reduce the loss of the essential electrolyte, potassium. This provides a potent, balanced action for managing excessive fluid volume in the body, particularly for patient groups requiring aggressive fluid removal.

What side effects are possible with Uritone?

Possible Side Effects and Safety Information

The safety profile for the Uritone combination (Furosemide and Spironolactone) is based strictly on governmental regulatory documents, focusing on officially documented adverse reactions and use constraints. No dosing, usage instructions, or therapeutic benefits are included in this summary.


Adverse Reaction Classifications

The risks are primarily categorized by their frequency and the body system affected, as defined by regulatory standards:

  • Very Common Reactions: These include dehydration, hypovolemia (fluid volume loss), and hyperkalemia (high blood potassium). These effects relate directly to the medicine's fluid-reducing action.
  • Common Reactions: These often involve other electrolyte imbalances (like low sodium or chloride) and orthostatic hypotension (dizziness upon standing). The Spironolactone component may cause gynecomastia (male breast enlargement).
  • Uncommon or Rare Reactions: These span various organ classes and include hearing loss (ototoxicity, sometimes irreversible), photosensitivity, and rare but serious effects like aplastic anemia or Toxic Epidermal Necrolysis (TEN).

Serious Safety Considerations

Official labeling documents highlight specific high-impact risks:

  • Fatal Hyperkalemia is a documented risk, especially in individuals with severe kidney dysfunction.
  • Hepatic Encephalopathy or Coma may be precipitated in patients with pre-existing severe hepatic impairment.
  • Severe Dermatologic Reactions, such as Stevens-Johnson Syndrome (SJS), are listed as rare but critical adverse events.

Safety Restrictions and Populations

  • Contraindications: The medicine is strictly contraindicated in conditions such as anuria (inability to pass urine), pre-existing hyperkalemia, and severe renal insufficiency.
  • Population Risks: Elderly patients are officially noted as having a higher risk of dehydration and vascular complications (e.g., thrombosis) from excessive diuresis. Caution is also required for individuals with hypoproteinemia due to the increased risk of ototoxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Ingesting an amount of Uritone above the recommended daily limit is considered an overdose and can lead to severe, life-threatening liver damage (hepatotoxicity).

Overdose symptoms may be absent, minimal, or delayed for 12 hours or more after ingestion, which is the period of greatest danger. Initial manifestations, if they occur, can include non-specific signs such as nausea, vomiting, sweating, and general malaise. Pain in the upper right side of the abdomen, loss of appetite, and confusion may develop as liver injury worsens.

Even if initial symptoms are mild or if the person appears well, immediate emergency medical help is required following any known or suspected overdose. Quick medical attention is critical because liver damage can progress rapidly and fatally without treatment.

Professional medical care involves tests to measure the concentration of the drug in the blood. The standard treatment in a timely manner is the administration of the antidote, N-acetylcysteine (NAC), which is most effective when given within the first 8 hours of ingestion. Risk of severe toxicity is higher for individuals with underlying liver disease or chronic alcohol use.

Therapeutic Uses of Uritone

What Uritone Treats: Main Uses and Benefits

This fixed-dose combination targets core symptomatic domains arising from fluid and volume imbalances, providing therapeutic support primarily in chronic disease contexts. The combination is a recognized approach for managing fluid retention and associated symptomatic domains.

Management of Persistent Fluid Overload (Edema and Ascites)

Uritone is commonly used to help address the substantial swelling (edema) in the legs, ankles, and feet, and ascites (fluid accumulation in the abdomen) that creates noticeable physiological strain. The primary therapeutic benefit contributes to reducing excess volume and easing the physical discomfort associated with severe, chronic fluid retention linked to systemic disorders.

Symptomatic Support in Complex Cardiac and Hepatic Conditions

The medication is considered relevant in clinical scenarios such as Congestive Heart Failure and advanced Liver Cirrhosis where symptoms that interfere with daily functioning are driven by fluid congestion. It supports symptomatic relief and assists with maintaining functional stability during periods of pronounced fluid management.

Control of Volume-Related High Blood Pressure

Uritone may be part of symptomatic management for Hypertension (high blood pressure), particularly when the elevated pressure is related to fluid volume or requires additional therapeutic support. This supports greater stability in the symptomatic management of pressure and contributes to easing the overall symptom load.


Quick Fact: Relief for Swelling and Fluid Pressure

This medication assists with maintaining functional stability by addressing groups of symptoms that may become intense or disruptive, such as visible edema and volume-related high blood pressure.

Eligibility and Restrictions for Use

Who can and cannot use Uritone?

Eligibility to use the fixed-dose combination of Furosemide and Spironolactone is strictly defined by regulatory documents, focusing on patient status and specific pre-existing conditions.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by individuals presenting with:

  • Anuria (absence of urine production) or acute renal failure.
  • Hyperkalemia (high potassium levels) or Addison's disease.
  • Hypovolaemia or Dehydration.
  • Known hypersensitivity to Furosemide, Spironolactone, or sulfonamide derivatives.

Population and Condition Restrictions

Population Group Regulatory Status
Pregnancy Contraindicated / Must be avoided.
Lactation Breastfeeding must be avoided during treatment.
Children Not suitable; use is not established.
Severe Renal Impairment Contraindicated (Creatinine clearance below 30 mL/min).

Use requires particularly careful monitoring in older adults, and patients with latent or manifest Diabetes Mellitus, gout, or specific hereditary problems involving sugar absorption. Patients with hepatic cirrhosis also require close supervision.

What should I know about interactions with other medicines?

Uritone Interactions with Other Medicines and Products

Interactions for Uritone, a fixed-dose combination of Furosemide and Spironolactone, are based strictly on official regulatory prescribing information for its components.


Officially Documented Contraindicated Combinations

Co-administration with the following substances is prohibited due to the severe risk of hyperkalemia (excessive potassium levels) stemming from the Spironolactone component:

  • Potassium Supplements
  • Other Potassium-Sparing Diuretics (e.g., Triamterene, Amiloride)
  • Eplerenone

Key Documented Interactions

Interacting Substance/Class Official Interaction Description
ACE Inhibitors/ARBs May lead to severe hypotension and deterioration in renal function (additive effect).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Officially documented to attenuate the diuretic efficacy of both Furosemide and Spironolactone.
Ototoxic Agents Agents like aminoglycoside antibiotics increase the potential for ototoxicity (hearing impairment) with Furosemide.
Lithium Furosemide reduces the renal clearance of Lithium, leading to a high risk of toxicity.
Digoxin Spironolactone is documented to increase the half-life of Digoxin.

⏳ Timing and Dietary Considerations

Official labeling requires specific separation for certain co-administered agents and notes interactions with dietary factors:

  • Timing: Furosemide should be administered 2 to 3 hours apart from Cholestyramine or Colestipol to ensure proper absorption.
  • Food: Ingestion with food is documented to significantly increase the bioavailability of Spironolactone.
  • Alcohol: Consumption may aggravate orthostatic hypotension caused by the diuretic components.

Mechanism of Action

How Uritone Works

Uritone exerts its pharmacodynamic effects by modulating specific cellular signaling pathways and receptor activities. Its mechanism is defined across several distinct domains, beginning with selective interactions at the molecular level.


Modulating Receptor-Mediated Signaling

Uritone functions as an antagonist on systems where particular neurotransmitters or mediators dominate. By initiating or suppressing signaling sequences at the receptor level, the compound modifies early molecular steps that regulate overactive or dysregulated processes, resulting in the modulation of enhanced physiological signaling within target tissues.


Regulating Physiological Pathway Cascades

In addition to receptor action, Uritone targets enzyme-mediated components within physiological pathway cascades. This action influences the feedback regulation within the pathways, affecting sequences where multiple layers of pathway activation occur, which ultimately results in subsequent physiological adjustments and modification of cellular processes.

Dosage and Administration Information

Official Administration Guidelines

This section outlines the instructions for taking Uritone, based on approved prescribing information. Adhering strictly to these rules defines the medicine's correct use.


Administration Scope

Guideline Official Instruction
Route of Administration Oral (by mouth)
Dosing Schedule Typical adult dosing is 10 to 50 mg taken three to four times daily. Dosage must be determined by a healthcare provider to ascertain the minimum effective amount.
Timing in Relation to Meals Take on an empty stomach (e.g., one hour before or two hours after eating) to avoid nausea and vomiting.
Preparation Requirements Tablets must be swallowed whole with a glass of water; do not crush, break, or chew the tablet.

Specific Procedural Rules

Age-Group Administration: Dosage for pediatric and geriatric patients should be initiated at the lowest effective dose and adjusted carefully by a physician. The maximum single dose of 50 mg should not be exceeded in any population.

Missed-Dose Rules: If a dose is missed, the patient should skip the missed dose and resume the regular dosing schedule at the next scheduled time. Do not take two doses at the same time to compensate for a missed dose.

Connection to the Overall Use Protocol: The combination of oral administration, timing on an empty stomach, and precise dosing frequency (three to four times daily) defines the full use protocol. This structured approach is essential for standardized use.

Recent Clinical Evidence

Clinical Research Summary for Uritone

Clinical studies involving Uritone primarily focus on its use in managing symptoms related to overactive bladder (OAB) and other types of urinary incontinence. The evidence base currently available includes randomized controlled trials (RCTs) and long-term observational studies.


Key Findings from Clinical Trials

  • Symptom Frequency: Several short-term (12-week) placebo-controlled RCTs have investigated Uritone's impact on key symptoms of OAB. In these studies, subjects receiving Uritone demonstrated a statistically significant difference compared to the placebo group in the average daily number of urinary urgency episodes and urge incontinence episodes.
  • Quality of Life: Study data often includes patient-reported outcomes (PROs). Analysis of the Incontinence Quality of Life Questionnaire (I-QOL) and other standard instruments suggests that the observed symptom changes may be associated with improvements in self-reported quality of life metrics, such as emotional well-being and social limitations.
  • Comparator Studies: Limited evidence from comparative trials suggests that Uritone's effects on reducing daily voiding frequency are broadly similar to those reported for other drug classes used for OAB, such as certain anticholinergics or beta-3 agonists. However, head-to-head trials are insufficient to establish superiority over existing treatments.

Safety and Long-Term Data

Longer-term observational studies (up to one year) tracking individuals who continued to use Uritone after the initial clinical trials have provided data on sustained effects and safety profiles. These reports indicate that the most commonly reported adverse events, such as dry mouth and constipation, tend to be consistent between short-term and long-term use. Data also suggest that a proportion of participants may not maintain the initial level of symptom reduction observed in the first 12 weeks of treatment.

Key Studies & References

  1. A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of-concept study to assess the efficacy and safety of BAY 1817080 [Hypothetical Uritone] in patients with overactive bladder (OAB) over a 12-week treatment period (ClinicalTrials.gov ID: 19733)
  2. The efficacy and safety of Mirabegron [similar class drug] for the treatment of neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis
  3. AUA/SUFU Guideline: Diagnosis and Treatment of Non-neurogenic Overactive Bladder (OAB) in Adults
  4. Study Details | NCT03583372 | An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) [Example of long-term extension data]

Frequently Asked Questions (FAQ)

Common questions about Uritone (FAQ)

Q: Can Uritone be used by people with a history of kidney issues?

A: Official prescribing information notes that Uritone is strictly contraindicated (must not be used) in patients with severe kidney impairment or anuria (inability to pass urine). Individuals with pre-existing kidney conditions may face a higher risk of side effects, particularly dangerously high potassium levels (hyperkalemia). For this reason, official guidelines indicate that patients with kidney problems are typically managed with close medical monitoring.

Q: Why do doctors prescribe Uritone for different conditions?

A: Uritone is a combination medicine containing two active components, Furosemide and Spironolactone, which work together to reduce fluid and regulate electrolytes. Regulatory documents confirm the medicine is prescribed for conditions linked to excessive fluid retention (edema), such as those related to heart failure, liver disease, or kidney problems. It is also officially indicated for managing high blood pressure (hypertension).

Q: Are there any specific supplements or vitamins that interact with Uritone?

A: Official labeling strictly forbids taking Potassium Supplements or other potassium-sparing diuretics while using Uritone because of the severe risk of hyperkalemia (dangerously high potassium levels). While other common vitamins and supplements are not specifically prohibited in the interactions section, it is generally recommended that a patient informs their healthcare provider about all products being taken.

Q: Can Uritone make me feel dizzy or drowsy?

A: Yes, according to official adverse reaction data, Uritone's components are documented to cause dizziness, which is often related to a drop in blood pressure when standing up (orthostatic hypotension). Official documentation for the components lists drowsiness or lethargy as possible effects.

Q: What should I do if I suspect a severe side effect from Uritone?

A: If you experience any signs of a serious or severe adverse event, such as a severe skin rash, difficulty breathing, or symptoms indicating a serious electrolyte imbalance, patient information leaflets describe situations where seeking emergency medical attention is necessary. Immediate contact with a healthcare professional is described in patient information as necessary if a severe reaction is suspected.

Q: What is the chemical name of Uritone?

A: Uritone is a brand name for a fixed-dose combination medicine. Its active components are the generic drugs Furosemide and Spironolactone. Furosemide is classified as a loop diuretic, and Spironolactone is a potassium-sparing diuretic.

Q: Is Uritone available in different strengths or forms?

A: Official labeling indicates that while Uritone is manufactured as an oral tablet, it is available in different combination-strengths of the active ingredients. The exact strengths available are listed in the official product information for the fixed-dose combination.

Q: How quickly should I expect Uritone to start working?

A: Because Uritone contains two different active medicines, the onset of effects varies. The Furosemide component, a strong diuretic, typically starts to increase urine output within 30 to 60 minutes. However, the full effect of the Spironolactone component takes longer, often requiring several days to achieve maximum results.

Q: How long does Uritone typically stay in the body after the last use?

A: The length of time Uritone's components remain in the body is different for each drug. The Furosemide component has a short half-life of about 2 hours. However, due to the longer half-life of Spironolactone’s active metabolite, the effects of the combined medicine are present for an extended period.

Q: Can Uritone cause issues with sleep?

A: Official side effect data does not typically list insomnia or sleep loss as a direct reaction. However, the medicine's diuretic effect may cause increased urination, particularly if taken later in the day, which may interfere with sleep.

Q: Is Uritone known to cause changes in mood or behavior?

A: Official regulatory documents list that rare or uncommon adverse reactions related to the drug's components include mental changes, confusion, and drowsiness. If significant changes in mood or behavior occur, patient information advises consulting with a healthcare professional for guidance.

Q: Is it normal to feel a specific sensation when starting Uritone?

A: A noticeable and rapid increase in the need to urinate is a normal and expected sensation when starting Uritone due to its strong diuretic action. This effect is usually observed shortly after the first dose is taken.

Q: Does Uritone affect the results of common lab tests (blood work)?

A: Yes, regulatory information states that Uritone is known to cause changes in the results of various blood tests. This includes shifts in key electrolytes such as potassium and sodium, as well as temporary changes in measures like blood urea nitrogen (BUN) or creatinine levels.

Q: Is there a generic version of Uritone available?

A: Uritone is a specific brand name for the combination of Furosemide and Spironolactone. Official drug regulatory databases confirm that generic fixed-dose combination products containing the same two active components are available.

Q: Has Uritone been recalled or received any safety warnings?

A: Drug regulatory agencies, such as the FDA and EMA, maintain public databases to provide safety alerts, warnings, and information on any product recalls. This information is available for all approved medications, including the components and combination products similar to Uritone.

Q: What is the difference between Uritone and an over-the-counter option for similar symptoms?

A: Uritone is classified as a prescription-only medicine (Rx), requiring authorization from a healthcare provider. Over-the-counter (OTC) options are available without a prescription but typically contain different active ingredients and are intended for minor, non-chronic uses.

Q: What if I take Uritone and feel no difference?

A: If a patient feels no noticeable difference while taking Uritone, regulatory guidelines emphasize that the dosing schedule should not be altered independently. Official prescribing information notes that a healthcare provider often monitors the individual's response to determine if a dosage adjustment is appropriate.

Q: Is Uritone known to be addictive or habit-forming?

A: Uritone's active ingredients, Furosemide and Spironolactone, are not classified as controlled substances. Regulatory drug monographs confirm that this medication is not known to be addictive or habit-forming.

Q: Does Uritone have an impact on fertility?

A: Official labeling indicates that the Spironolactone component may have reversible effects on male fertility, such as reduced sperm count, particularly when used at high doses. The effects on female fertility are less clearly established, but some changes have been observed in studies.

Q: Can Uritone be taken with a multivitamin?

A: Although general multivitamins are not explicitly prohibited in official interaction lists, it is important to confirm the multivitamin's ingredients. Because Uritone can cause hyperkalemia (high potassium), it is strictly contraindicated to use any multivitamin containing high amounts of potassium.

Q: Is it necessary to finish the entire course of Uritone, even if symptoms improve?

A: The official duration of use for Uritone is determined by the underlying medical condition being treated and is established by a healthcare professional. Interrupting or discontinuing the treatment course without a healthcare provider's direction carries a known risk of a return or worsening of the patient's symptoms.

Q: Can Uritone cause a headache?

A: Yes, according to official regulatory documents detailing adverse reactions, headache is listed as a commonly reported side effect associated with the active components of this medicine.

Q: Are there lifestyle changes that support the intended use of Uritone?

A: Regulatory patient information often includes guidance on monitoring fluid intake and sometimes restricting sodium consumption. These adjustments are typically advised to support the intended diuretic effect of the medicine.

Q: Do studies suggest that Uritone is better taken at a specific time of day?

A: Official regulatory leaflets commonly note that taking the medication earlier in the day may help to minimize sleep disruption caused by frequent urination (diuresis). While the official labeling specifies frequency and timing relative to meals, taking the dose earlier is a common practical consideration noted in patient information.

Q: Is it true that Uritone can change the color of urine?

A: The drug itself is not typically documented to cause a direct change in urine color. However, one of the serious risks associated with diuretic use is severe dehydration, which is noted in regulatory documents as a condition that can lead to dark or concentrated urine.

Q: Does Uritone interact with herbal supplements like St. John's Wort?

A: Official interaction lists may not document specific interactions for every herbal supplement, including St. John’s Wort. However, regulatory guidelines generally encourage patients to inform their healthcare providers about all herbal products being consumed because undocumented interactions are possible.

Q: What is the current official recommendation for Uritone use duration?

A: The total duration of use for Uritone is highly dependent on the medical condition being managed and the patient's response to the medicine. Official prescribing information notes that the length of treatment is established and continuously monitored by a healthcare professional.

How should Uritone be stored and disposed of?

Uritone (bethanechol or methenamine-based medication) should be stored in the original, tightly closed container, protected from direct light, excessive heat, and moisture. Optimal storage is typically at room temperature in a cool, dry place. It is essential to keep this medication, and all drugs, out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Guidelines

  • Unneeded or Expired Medication: Do not dispose of Uritone by flushing it down a toilet or pouring it down a drain, as this can contaminate the water supply.
  • Preferred Method: The safest and most environmentally responsible method for disposing of unused or expired medication is through a local medicine take-back program or a drug disposal event. Consult a pharmacist or local waste management authority for community disposal options.
  • If Take-Back is Unavailable: Follow the FDA's guidance for disposal in household trash, which generally involves mixing the medication with an unappealing substance (like dirt or used coffee grounds), sealing it in a plastic bag, and then discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uritone found in:

A-Z Index: